In World Antimicrobial Resistance Awareness Week (WAAW), Applied Microbiology International (AMI) has urged global policymakers to strengthen the revised Global Action Plan on Antimicrobial Resistance (GAP-AMR), calling for a more inclusive, clear and equitable approach to tackling one of the world’s most urgent health challenges.

Apriori Bio, a Flagship Pioneering portfolio company, and the Agency for Science, Technology and Research Infectious Diseases Labs (A*STAR IDL) have announced a research collaboration to co-develop self-amplifying RNA (saRNA) vaccine candidates targeting H5 influenza. The partnership combines Apriori’s Octavia™ AI-guided antigen-design platform with A*STAR IDL’s saRNA delivery technology and infectious-disease expertise, advancing breakthrough solutions for the advancement of human health, supporting the development of next-generation vaccines and contributing to Singapore’s growth as a global hub for biomedical innovation.

In a surprising discovery, a ‘sticky molecule’ that occurs naturally in our blood vessels could be both a culprit behind blood clots and organ failure during COVID and long COVID and the key to new treatments to counter COVID-related viruses.

The American College of Physicians (ACP) issued new influenza vaccine practice points that say everyone ages 18 to 64 years who are not pregnant or immunocompromised should receive either a standard-dose trivalent or a standard-dose quadrivalent (cell-based, egg-based, MF59-adjuvanted, or recombinant) influenza vaccine for the 2025-2026 influenza season.

About The Study: Approximately 1 in 30 trials and more than 74,000 trial participants were affected by grant funding disruptions. Affected trials disproportionately studied infectious diseases, prevention, and behavioral interventions, and were based in the Northeastern U.S. or in other countries. Because trials require sustained financial support to ensure operations and participant safety, unanticipated funding disruptions raise concerns about avoidable waste, data quality, and compromised ethical obligations to participants. 

Embargoed press materials are now available for the Association for Molecular Pathology 2025 Annual Meeting & Expo.